Alison Armour

16.2k total citations · 4 hit papers
37 papers, 11.5k citations indexed

About

Alison Armour is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Alison Armour has authored 37 papers receiving a total of 11.5k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Pulmonary and Respiratory Medicine, 24 papers in Oncology and 10 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Alison Armour's work include Lung Cancer Treatments and Mutations (21 papers), Colorectal Cancer Treatments and Studies (11 papers) and Lung Cancer Research Studies (10 papers). Alison Armour is often cited by papers focused on Lung Cancer Treatments and Mutations (21 papers), Colorectal Cancer Treatments and Studies (11 papers) and Lung Cancer Research Studies (10 papers). Alison Armour collaborates with scholars based in United Kingdom, United States and Japan. Alison Armour's co-authors include Tony Mok, Yi‐Long Wu, Emma Duffield, Claire Watkins, Masahiro Fukuoka, Haiyi Jiang, Nagahiro Saijo, James Chih‐Hsin Yang, Sumitra Thongprasert and Patrapim Sunpaweravong and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Alison Armour

37 papers receiving 11.3k citations

Hit Papers

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocar... 2008 2026 2014 2020 2009 2021 2011 2008 2.0k 4.0k 6.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
    2009 6.4k citations Tony Mok, Yi‐Long Wu et al. New England Journal of Medicine profile →
  2. Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
    2021 1.5k citations Oliver Sartor, Alison Armour et al. New England Journal of Medicine profile →
  3. Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
    2011 1.2k citations Masahiro Fukuoka, Yi‐Long Wu et al. Journal of Clinical Oncology profile →
  4. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
    2008 1.0k citations Edward S. Kim, Vera Hirsh et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Alison Armour United Kingdom 18 9.6k 7.4k 2.6k 2.3k 1.4k 37 11.5k
Christian Manegold Germany 39 13.0k 1.4× 9.4k 1.3× 3.2k 1.2× 1.9k 0.8× 1.1k 0.8× 113 16.2k
Sara M. Haserlat United States 9 7.0k 0.7× 6.2k 0.8× 3.7k 1.4× 2.3k 1.0× 636 0.5× 10 9.8k
Patricia L. Harris United States 11 7.5k 0.8× 6.7k 0.9× 4.0k 1.6× 2.3k 1.0× 698 0.5× 15 10.6k
Yukito Ichinose Japan 42 11.3k 1.2× 8.7k 1.2× 3.0k 1.2× 2.4k 1.0× 758 0.5× 229 13.9k
Robert T. Heelan United States 38 7.2k 0.7× 5.5k 0.7× 2.5k 1.0× 1.5k 0.7× 1.0k 0.7× 78 9.7k
A Płużańska Poland 28 8.3k 0.9× 6.3k 0.9× 3.2k 1.3× 2.9k 1.3× 1.4k 1.0× 65 11.6k
Ross A. Okimoto United States 20 8.1k 0.8× 7.3k 1.0× 4.9k 1.9× 2.7k 1.2× 738 0.5× 33 12.1k
Rodryg Ramlau Poland 43 9.1k 0.9× 8.9k 1.2× 3.1k 1.2× 1.6k 0.7× 547 0.4× 245 12.8k
Steven D. Averbuch United States 27 7.5k 0.8× 8.0k 1.1× 2.9k 1.1× 1.6k 0.7× 738 0.5× 59 11.0k
U. Gatzemeier Germany 42 12.3k 1.3× 10.7k 1.4× 3.6k 1.4× 1.8k 0.8× 764 0.6× 184 16.3k

Countries citing papers authored by Alison Armour

Since Specialization
Citations

This map shows the geographic impact of Alison Armour's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alison Armour with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alison Armour more than expected).

Fields of papers citing papers by Alison Armour

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alison Armour. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alison Armour. The network helps show where Alison Armour may publish in the future.

Co-authorship network of co-authors of Alison Armour

This figure shows the co-authorship network connecting the top 25 collaborators of Alison Armour. A scholar is included among the top collaborators of Alison Armour based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alison Armour. Alison Armour is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Morris, Michael J., Nicholas J. Vogelzang, Oliver Sartor, et al.. (2017). Phase 1 study of the PSMA-targeted small-molecule drug conjugate EC1169 in patients with metastatic castrate-resistant prostate cancer (mCRPC). Annals of Oncology. 28. v273–v273. 5 indexed citations
2.
Morris, Michael J., Nicholas J. Vogelzang, Oliver Sartor, et al.. (2016). Phase 1 study of the PSMA-targeted tubulysin small-molecule drug conjugate EC1169 in patients with metastatic castrate-resistant prostate cancer (mCRPC): Study update. Annals of Oncology. 27. vi249–vi249. 3 indexed citations
3.
Shi, Wenhao, Tingting Jiang, Paolo Nucíforo, et al.. (2016). Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial. Annals of Oncology. 28(1). 128–135. 51 indexed citations
4.
Sachdev, Jasgit C., et al.. (2016). Phase 1 dose-escalation study of the folic acid-tubulysin small-molecule drug conjugate (SMDC) folate-tubulysin EC1456: Study update. Annals of Oncology. 27. vi126–vi126. 5 indexed citations
5.
Pusztai, Lajos, Tingting Jiang, Paolo Nucíforo, et al.. (2015). Whole exome sequencing of pre-treatment biopsies from the neoALTTO trial to identify DNA aberrations associated with response to HER2-targeted therapies. Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles). 1 indexed citations
6.
Inoue, Kenichi, Katsumasa Kuroi, Satoru Shimizu, et al.. (2015). Safety, pharmacokinetics and efficacy findings in an open-label, single-arm study of weekly paclitaxel plus lapatinib as first-line therapy for Japanese women with HER2-positive metastatic breast cancer. International Journal of Clinical Oncology. 20(6). 1102–1109. 8 indexed citations
7.
Thongprasert, Sumitra, Emma Duffield, Nagahiro Saijo, et al.. (2011). Health-Related Quality-of-Life in a Randomized Phase III First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients from Asia with Advanced NSCLC (IPASS). Journal of Thoracic Oncology. 6(11). 1872–1880. 107 indexed citations
8.
Armour, Alison & Claire Watkins. (2010). The challenge of targeting EGFR: experience with gefitinib in nonsmall cell lung cancer. European Respiratory Review. 19(117). 186–196. 33 indexed citations
9.
Mok, Tony, Yi‐Long Wu, Sumitra Thongprasert, et al.. (2009). Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma. New England Journal of Medicine. 361(10). 947–957. 6355 indexed citations breakdown →
10.
Stewart, J.S.W., Ezra E.W. Cohen, Lisa Licitra, et al.. (2009). Phase III Study of Gefitinib Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck. Journal of Clinical Oncology. 27(11). 1864–1871. 267 indexed citations
11.
Kudoh, Shoji, Harubumi Kato, Yutaka Nishiwaki, et al.. (2008). Interstitial Lung Disease in Japanese Patients with Lung Cancer. American Journal of Respiratory and Critical Care Medicine. 177(12). 1348–1357. 365 indexed citations
12.
Kim, Edward S., Vera Hirsh, Tony Mok, et al.. (2008). Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. The Lancet. 372(9652). 1809–1818. 1009 indexed citations breakdown →
13.
Douillard, Jean‐Yves, Vera Hirsh, Tony Mok, et al.. (2008). Molecular and clinical subgroup analyses from a phase III trial comparing gefitinib with docetaxel in previously treated non-small cell lung cancer (INTEREST). Journal of Clinical Oncology. 26(15_suppl). 8001–8001. 27 indexed citations
14.
Stewart, J.S.W., Ezra E.W. Cohen, Lisa Licitra, et al.. (2007). A Phase III randomized parallel-group study of gefitinib (IRESSA) versus methotrexate (IMEX) in patients with recurrent squamous cell carcinoma of the head and neck. Cancer Research. 67. 3522–3522. 18 indexed citations
15.
Crinò, Lucio, Petr Zatloukal, Martin Reck, et al.. (2007). B3-04: Gefitinib (IRESSA) versus vinorelbine in chemonaïve elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized Phase II study. Journal of Thoracic Oncology. 2(8). S341–S341. 19 indexed citations
16.
17.
Ross, Gayle, et al.. (2004). A case of squamous cell carcinoma associated with plasmacytoma. British Journal of Plastic Surgery. 57(2). 172–173. 2 indexed citations
18.
Armour, Alison, et al.. (2000). Late Radiation Side-Effects in Three Patients Undergoing Parotid Irradiation for Benign Disease. Clinical Oncology. 12(6). 403–408. 5 indexed citations
19.
Bolger, B., et al.. (2000). Apoptosis in cervical squamous carcinoma: predictive value for survival following radiotherapy. Journal of Clinical Pathology. 53(3). 197–200. 16 indexed citations
20.
Armour, Alison, et al.. (1993). Ectopic cervical hamartomatous thymoma showing extensive myoid differentiation. The Journal of Laryngology & Otology. 107(2). 155–158. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Christian Manegold Breakdown of academic impact, for papers by Sara M. Haserlat Breakdown of academic impact, for papers by Patricia L. Harris Breakdown of academic impact, for papers by Yukito Ichinose Breakdown of academic impact, for papers by Robert T. Heelan Breakdown of academic impact, for papers by A Płużańska Breakdown of academic impact, for papers by Ross A. Okimoto Breakdown of academic impact, for papers by Rodryg Ramlau Breakdown of academic impact, for papers by Steven D. Averbuch Breakdown of academic impact, for papers by U. Gatzemeier
Rankless by CCL
2026